Corporate calendar for Kazia Therapeutics Ltd ADR (KZIA): upcoming earnings dates, dividend ex-dates and payment dates, stock splits, shareholder meetings and conference calls. Plan your positions around the key catalysts.
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous...
Price
| Price | $10.20 |
| Market Cap | $17M |
| Exchange | NASDAQ |
| Country | AU |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 3 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 3 |
| Avg rating (1-5) | 1.00 |
Related companies: BDRX · CANF · CMND · CNSP · GRI · INM · OGEN
Explore sector: Healthcare · Biotechnology
More sections of KZIA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · News
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks